New York, USA, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Primary Myelofibrosis Pipeline Space Brims With Novel Emerging Therapies with Over 50 Key Companies Working in the Domain | DelveInsight
Primary myelofibrosis Pipeline constitutes 50+ key companies continuously working towards developing 55+ primary myelofibrosis treatment therapies, analyzes DelveInsight
DelveInsight’s 'Primary Myelofibrosis Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline primary myelofibrosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the primary myelofibrosis pipeline domain.
Key Takeaways from the Primary Myelofibrosis Pipeline Report
- DelveInsight’s primary myelofibrosis pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for primary myelofibrosis treatment.
- Key primary myelofibrosis companies such as Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences, Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others are evaluating new drugs for primary myelofibrosis to improve the treatment landscape.
- Promising primary myelofibrosis pipeline therapies in various stages of development include NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat, KER-050, GB 2064, TL-895, TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225, DISC-0974, BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744, JAB-8263, Tasquinimod, Mivebresib, 9-ING-41, Itacitinib, PU-H-71, Selinexor, and others.
- In June 2022, Cellenkos announced that the US Food and Drug Administration (FDA) had cleared its Investigational New Drug (IND) application to initiate a Phase Ib, open-label study of CK0804 as an add-on therapy to ruxolitinib in patients with myelofibrosis who experience a suboptimal response to ruxolitinib.
- In June 2022, Imago Biosciences presented updated positive data from its ongoing global Phase II clinical study evaluating bomedemstat in patients with advanced myelofibrosis. Bomedemstat was generally safe and well-tolerated in patients with myelofibrosis.
- In June 2022, announced the US FDA granted Orphan Drug Designation for TP-3654, Sumitomo Pharma Oncology's proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis.
- In June 2022, AbbVie announced new data from Cohort 3 of its Phase II REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis (MF), a rare and difficult to treat blood cancer. These data reinforced the importance of early intervention in myelofibrosis and the potential to achieve improved clinical outcomes.
- In February 2022, Active Biotech entered into an exclusive license agreement with Oncode Institute in the Netherlands for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in the treatment of myelofibrosis.
Request a sample and discover the recent advances in primary myelofibrosis treatment drugs @Primary Myelofibrosis Pipeline Report
The primary myelofibrosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage primary myelofibrosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the primary myelofibrosis clinical trial landscape.
Primary Myelofibrosis Overview
Primary myelofibrosis is a disorder in which normal bone marrow tissue is gradually replaced by fibrous scar-like material. Primary myelofibrosis progressive bone marrow failure over time. Under normal circumstances, the bone marrow provides a fine network of fibers for stem cells to divide and grow on.
Feelings of discomfort, pain, or fullness in the upper left side of the abdomen are common symptoms. An enlarged spleen can also pressure the stomach, causing bloating, indigestion, and a loss of appetite. A physical examination that reveals an enlarged spleen, blood tests, and a bone marrow examination are used for primary myelofibrosis diagnosis.
Primary myelofibrosis is generally thought to be an incurable disease, but with primary myelofibrosis treatment, many people can live comfortably and symptom-free for a long time. The disease’s natural course can vary significantly between individuals.
Find out more about primary myelofibrosis treatment drugs @Drugs for Primary Myelofibrosis Treatment
A snapshot of the Primary Myelofibrosis Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Pelabresib | MorphoSys | Phase III | Bromodomain and extraterminal domain protein inhibitor | Oral |
| Navitoclax | AbbVie | Phase III | Apoptosis stimulant; Proto-oncogene protein c-bcl-2 inhibitor | Oral |
| KRT-232 | Kartos Therapeutics | Phase II/III | Proto-oncogene protein c mdm2 inhibitor | Oral |
| NS 018 | Nippon Shinyaku | Phase II | Janus kinase-2 inhibitor; Src-Family kinase inhibitor | Oral |
| GB-2064 | Galecto | Phase II | LOXL2 protein inhibitors | Oral |
| TP 3654 | Sumitomo Pharma Oncology | Phase I/II | 1 Phosphatidylinositol 3 kinase inhibitor; Proto oncogene proteins c pim 1 inhibitor | Oral |
| LNK01002 | Lynk Pharmaceuticals | Phase I | Protein kinase inhibitor | Oral |
Learn more about the emerging primary myelofibrosis pipeline therapies @Primary Myelofibrosis Clinical Trials
Primary Myelofibrosis Therapeutics Assessment
The primary myelofibrosis pipeline report proffers an integral view of primary myelofibrosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Primary Myelofibrosis Pipeline Report
- Coverage: Global
- Primary Myelofibrosis Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Primary Myelofibrosis Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Primary Myelofibrosis Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Primary Myelofibrosis Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule, Antibody
- Primary Myelofibrosis Therapeutics Assessment By Mechanism of Action: Janus kinase-2 inhibitors, Src-Family kinase inhibitors, Proto-oncogene protein c mdm2 inhibitors, 1 Phosphatidylinositol 3 kinase inhibitors, Proto oncogene proteins c pim 1 inhibitors, Bromodomain and extraterminal domain protein inhibitors, TGF-beta superfamily protein inhibitors, Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors, Telomerase inhibitors, Erythropoiesis stimulants; Transforming growth factor beta inhibitors, BRD2 protein inhibitors; BRD3 protein inhibitors; BRD4 protein inhibitors
- Key Primary Myelofibrosis Companies: Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, Pharmaxis, MorphoSys, Merck & Co, AbbVie, Suzhou Zelgen Biopharmaceuticals, Geron Corporation, Keros Therapeutics, Galecto, Telios Pharma, Chia Tai Tianqing Pharmaceutical Group, Imago BioSciences, Roche, Incyte Corporation, Disc Medicine, Inc, Bristol-Myers Squibb, Lynk Pharmaceuticals, Samus Therapeutics, Taiga Biotechnologies, Cellenkos, Jacobio Pharmaceuticals, Active Biotech, Actuate Therapeutics, Samus Therapeutics, Karyopharm Therapeutics, and others
- Key Primary Myelofibrosis Pipeline Therapies: NS 018, KRT-232, TP 3654, PXS 5505, Pelabresib, ACE-536, Navitoclax, Jaktinib, Imetelstat, KER-050, GB 2064, TL-895, TQ05105, Bomedemstat, RO7490677, INCB000928, LDE225, DISC-0974, BMS-986158, BMS 986416, LNK01002, PU-H71, TBX-2400, CK0804, ABBV-744, JAB-8263, Tasquinimod, Mivebresib, 9-ING-41, Itacitinib, PU-H-71, Selinexor, and others.
Dive deep into rich insights for new drugs for primary myelofibrosis treatment; visit @Primary Myelofibrosis Medications
Table of Contents
| 1. | Primary Myelofibrosis Pipeline Report Introduction |
| 2. | Primary Myelofibrosis Pipeline Report Executive Summary |
| 3. | Primary Myelofibrosis Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Primary Myelofibrosis Clinical Trial Therapeutics |
| 6. | Primary Myelofibrosis Pipeline: Late Stage Products (Phase III) |
| 6.1 | Pelabresib: MorphoSys |
| 7. | Primary Myelofibrosis Pipeline: Mid Stage Products (Phase II) |
| 7.1 | NS-018: Nippon Shinyaku |
| 8. | Primary Myelofibrosis Pipeline: Early Stage Products (Phase I) |
| 8.1 | TP 3654: Sumitomo Pharma Oncology |
| 10. | Primary Myelofibrosis Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Primary Myelofibrosis Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Primary Myelofibrosis Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the primary myelofibrosis pipeline therapeutics, reach out @Primary Myelofibrosis Treatment Drugs
Related Reports
Primary Myelofibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key primary myelofibrosis companies including Nippon Shinyaku, Kartos Therapeutics, Sumitomo Pharma Oncology, among others.
Primary Myelofibrosis Epidemiology Forecast
Primary Myelofibrosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted primary myelofibrosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Myelofibrosis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myelofibrosis companies, including Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, among others.
Myelofibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key myelofibrosis companies including Geron Corporation, AbbVie, Sierra Oncology, Galecto Biotech, Actuate Therapeutics, Kartos Therapeutics, among others.
Post-Polycythemia Vera Myelofibrosis Pipeline
Post-Polycythemia Vera Myelofibrosis Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key post-polycythemia vera myelofibrosis companies, including Sierra Oncology Inc., CTI Biopharma Corp., Incyte Corporation, Imago BioSciences, Inc., among others.
Post-Polycythemia Vera Myelofibrosis Market
Post-Polycythemia Vera Myelofibrosis Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key post-polycythemia vera myelofibrosis companies including Sierra Oncology Inc., CTI Biopharma Corp., Incyte Corporation, Imago BioSciences, Inc. among others.
Other Trending Reports
Goitre Market | Thymus Cancer Market | US Healthcare Outlook Report | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Weight Loss/Weight Management (Obesity) Market | Food Allergy Market | Obsessive-Compulsive Disorder Market | Tumor Ablation Market | Physiotherapy Equipment Market | Chimeric Antigen Receptor (CAR) T-Cell Therapy Market | Anti-hypertension Market | Radiofrequency Ablation Devices Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market | Gastro Intestinal Bleeding Market | Trastuzumab Biosimilars Insight | Varicose Veins Market | Germ Cell Tumor Market | Intracardiac Echocardiography Devices Market | India Healthcare Report | Crows Feet Market | Seborrhoeic Dermatitis Market | Injectable Drug Delivery Devices Market | Structural Heart Devices Market | Substance (Drug) Abuse Market | Insulin Glargine Biosimilar Insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
